Cargando…
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large‐cell lym...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879058/ https://www.ncbi.nlm.nih.gov/pubmed/29488330 http://dx.doi.org/10.1111/1759-7714.12613 |
_version_ | 1783310927094874112 |
---|---|
author | Du, Xue Shao, Yun Qin, Hai‐Feng Tai, Yan‐Hong Gao, Hong‐Jun |
author_facet | Du, Xue Shao, Yun Qin, Hai‐Feng Tai, Yan‐Hong Gao, Hong‐Jun |
author_sort | Du, Xue |
collection | PubMed |
description | The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large‐cell lymphoma. Since then, ALK has been associated with other types of cancers, including non‐small‐cell lung cancer (NSCLC). More than 19 different ALK fusion partners have been discovered in NSCLC, including EML4, KIF5B, KLC1, and TPR. Most of these ALK fusions in NSCLC patients respond well to the ALK inhibitor, crizotinib. In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK‐rearrangement (ALK‐R), and the ALK‐tyrosine kinase inhibitor, crizotinib, used in NSCLC patients. |
format | Online Article Text |
id | pubmed-5879058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-58790582018-04-04 ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) Du, Xue Shao, Yun Qin, Hai‐Feng Tai, Yan‐Hong Gao, Hong‐Jun Thorac Cancer Invited Review The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large‐cell lymphoma. Since then, ALK has been associated with other types of cancers, including non‐small‐cell lung cancer (NSCLC). More than 19 different ALK fusion partners have been discovered in NSCLC, including EML4, KIF5B, KLC1, and TPR. Most of these ALK fusions in NSCLC patients respond well to the ALK inhibitor, crizotinib. In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK‐rearrangement (ALK‐R), and the ALK‐tyrosine kinase inhibitor, crizotinib, used in NSCLC patients. John Wiley & Sons Australia, Ltd 2018-02-28 2018-04 /pmc/articles/PMC5879058/ /pubmed/29488330 http://dx.doi.org/10.1111/1759-7714.12613 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Invited Review Du, Xue Shao, Yun Qin, Hai‐Feng Tai, Yan‐Hong Gao, Hong‐Jun ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) |
title |
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) |
title_full |
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) |
title_fullStr |
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) |
title_full_unstemmed |
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) |
title_short |
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) |
title_sort | alk‐rearrangement in non‐small‐cell lung cancer (nsclc) |
topic | Invited Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879058/ https://www.ncbi.nlm.nih.gov/pubmed/29488330 http://dx.doi.org/10.1111/1759-7714.12613 |
work_keys_str_mv | AT duxue alkrearrangementinnonsmallcelllungcancernsclc AT shaoyun alkrearrangementinnonsmallcelllungcancernsclc AT qinhaifeng alkrearrangementinnonsmallcelllungcancernsclc AT taiyanhong alkrearrangementinnonsmallcelllungcancernsclc AT gaohongjun alkrearrangementinnonsmallcelllungcancernsclc |